Anemia Drugs Market to Grow at a Steady CAGR of 6.83% During 2025-30

• Overview
• Table of Content
• Research Methodology
• Download Free Sample

Global Anemia Drugs Market Overview, Trends, Size and Forecast: 2025-2030

The Global Anemia Drugs Market size was valued at around USD14.62 billion in 2024 and is projected to reach USD21.73 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 6.83% during the forecast period, i.e., 2025-30, cites MarkNtel Advisors in the recent research report. The main reason behind the growth of this market is the rise in anemia cases and awareness of it globally. Other factors include poor diet, underlying illnesses, and limited access to healthcare in low and medium-income countries.

Responding to the prevalence of this disorder, countries have intensified their efforts in combating anemia, driving opportunities in the anemia drugs market for pharmaceutical companies. For instance, the launch of Ethiopia’s National Food Fortification Program in 2024 mandated the fortification of wheat flour and edible oil with essential micronutrients, also directing public institutions to allocate budgets for premix procurement. This resulted in the rise in contracts for several pharmaceutical suppliers in the anemia drugs market. Even though such efforts exist, anemia continues to affect the health of the public, particularly among the vulnerable population. For instance, a 2023 systematic review and meta-analysis in BMC Public Health showed that globally, roughly 60% of adults aged 60 years and above suffer from anemia, which peaks in Kerala, India at 92.8% and reaches a low of 8.4% in Assam, India at 8.4%. This presents a large but underserved geriatric patient pool, which converts to a key opportunity for pharmaceutical companies specializing in anemia treatment.

Moreover, an important driver for the expansion of the market is the innovations in drug technology. For instance, patients now have convenient and accessible options for injectable treatments in the form of oral HIF-prolyl hydroxylase (HIF-PH) inhibitors, such as roxadustat and daprodustat. Additionally, in 2023, the FDA approved Jesduvroq (daprodustat), which is the first once-a-day oral medication for anemia associated with chronic kidney disease (CKD) in adults who are on dialysis. These innovations have improved the adherence and treatment options and increased the market growth due to the steady demands of the patient, further states the research report, “Global Anemia Drugs Market Analysis, 2025.”

Global Anemia Drugs Market Segmentation Insights:

Iron-Deficiency Anemia Generating Maximum Market Revenue

Based on the anemia type, the market is further segmented into Iron-Deficiency Anemia, Pernicious Anemia, Aplastic Anemia, Hemolytic Anemia, Sickle Cell Anemia, Thalassemia, and Others. Iron deficiency anemia (IDA) has the largest share, around 45% in the Global Anemia Drugs Market, as it afflicts the population the most among all anemia types. This condition is caused due to insufficient iron in the diet and is particularly pronounced in vulnerable populations, such as women of reproductive age and young children. Additionally, there is increased adoption of high-strength intravenous (IV) iron therapies and the development of novel oral drugs due to IDA’s global prevalence. For instance, ferric carboxymaltose gained popularity as it can restore iron levels easily and quickly with just a few infusions, which made it preferable over traditional oral supplements, which are often plagued by poor patient compliance because of their side effects in the digestive system. This is an opportunity as the market players can make use of these advanced treatments for iron deficiency, particularly in patients with chronic illnesses, like CKD, where oral iron drugs are often ineffective.

Global Anemia Drugs Market Regional Analysis:

North America Leading the Anemia Drugs Industry Globally

Regionally, North America leads the Global Anemia Drugs Market for therapeutics, particularly within the iron deficiency treatments. It is projected to continue growth in the forecast period because of several factors, such as high healthcare and R&D spending, high concentration of pharmaceutical companies, patients with chronic conditions like kidney disease, cancer, and heart failure that result in a constant need for oral and injectable medications across hospitals, dialysis centers, and oncology clinics. Additionally, there is broad insurance coverage and proactive screening programs, which aid in the early diagnosis and prompt treatment of anemia, driving the demand in the market.

Moreover, FDA approvals happen regularly in the region, helping in the fast adoption of innovative anemia treatments into clinical practices. This, combined with the persistent patient population requiring anemia care, ensures that North America will continue to maintain its lead in the market for the forecast period.

Top Companies in the Global Anemia Drugs Market

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading Anemia Drugs Market companies, including Amgen Inc., Pfizer Inc., GlaxoSmithKline plc, Biocon Ltd., Bluebird bio, Inc., Eli Lily and Company, Johnson & Johnson Services, Inc., Bayer AG, GlycoMimetics, Inc., Regen Biopharma Inc., Acceleron Pharma, F. Hoffmann-La Roche Ltd., Novartis AG, Zydus Lifesciences Ltd. and others, are looking forward to increasing their market size & share.

Key Questions Answered in the Research Report

1. What is the scope, size, value, and forecast of the Anemia Drugs Market?
2. What is the volume and share of each segment in the Anemia Drugs Market?
3. What are the key trends shaping the Anemia Drugs Market from 2025 to 2030?
4. What growth factors and risks impact the Anemia Drugs Market?
5. What are the main challenges faced by players in the Anemia Drugs Market?
6. What are the top opportunities in the Anemia Drugs Market?
7. What does competitive analysis reveal about the Anemia Drugs Market landscape?
8. Who are the key players and companies leading the Anemia Drugs Market?
9. What innovations are transforming the future dynamics of the Anemia Drugs Market?
10. How are partnerships and collaborations driving the Anemia Drugs Market?
11. How does the Anemia Drugs Market differ based on geography and segments?